| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
The primary target of SEMBL is the transcription factor NF-κB, specifically the p65 component. NF-κB is a key regulator of inflammatory and immune responses, as well as cell survival and proliferation. By inhibiting the DNA binding of p65, SEMBL prevents NF-κB from activating the transcription of its target genes, including those encoding inflammatory cytokines. This mechanism underlies its anti-inflammatory and anticancer activities.
|
|---|---|
| ln Vitro |
In ovarian cancer cells, SEMBL suppresses MMP-2 expression and cell metastatic activity [1]. In ES-2 nuclear extracts, SEMBL blocks NF-κB's free DNA binding, and in ovarian cancer cells, it suppresses constitutively active NF-κB activity [1]. At non-toxic concentrations, SEMBL suppresses the migration, invasion, and MMP-2 production of ovarian cancer cells [1].
In vitro, SEMBL is a potent inhibitor of NF-κB-DNA binding activity. It inhibits the DNA binding of the NF-kappaB component p65 in vitro. By blocking NF-κB, it suppresses NF-κB-dependent inflammatory cytokine secretion. The compound also inhibits cellular invasion in ovarian carcinoma ES-2 cells, demonstrating its potential as an anticancer agent. |
| ln Vivo |
In vivo, SEMBL has been studied for its potential in treating inflammatory and neoplastic diseases. Its ability to inhibit NF-κB and reduce inflammatory cytokine secretion makes it a promising candidate for research into conditions driven by NF-κB activation. The compound's in vivo efficacy and pharmacokinetic properties have been characterized in preclinical studies.
|
| Enzyme Assay |
In vitro binding studies for SEMBL measure its inhibition of NF-κB-DNA binding. Electrophoretic mobility shift assays (EMSA) or enzyme-linked immunosorbent assays (ELISA) are used to assess the binding of the p65 subunit to its DNA consensus sequence in the presence of the compound. The compound's ability to inhibit this interaction is quantified, and IC₅₀ values are determined.
|
| Cell Assay |
In vitro cell-based assays for SEMBL evaluate its effects on NF-κB-dependent gene expression and cellular functions. Cells are treated with the compound, and the expression of NF-κB target genes, such as those encoding inflammatory cytokines, is measured by qRT-PCR or ELISA. The compound's effects on cell proliferation and invasion are assessed using standard assays.
|
| Animal Protocol |
In vivo animal studies for SEMBL are conducted in models of inflammation and cancer. The compound is administered via intraperitoneal or oral routes. Its effects on inflammatory cytokine levels and tumor growth are assessed. Pharmacodynamic studies measure NF-κB activity in target tissues. Pharmacokinetic studies determine the compound's half-life and bioavailability.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of SEMBL have been characterized in preclinical studies. Its molecular weight is 233.22 g/mol. The compound has a density of 1.36 g/cm³. For research use, it is stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 1 year. Further details on its half-life, Cmax, and bioavailability are available from the primary research literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of SEMBL has not been extensively detailed in the available literature. It is classified for research use only and not for human consumption. As an NF-κB inhibitor, its potential side effects may include immunosuppression. Standard safety precautions for handling bioactive compounds should be followed.
|
| References | |
| Additional Infomation |
Additional information: SEMBL is a novel inhibitor of NF-κB-DNA binding. It suppresses NF-κB-dependent inflammatory cytokine secretion. The compound has significant applications in anticancer and anti-inflammatory research. This product is for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C12H11NO4
|
|---|---|
| Molecular Weight |
233.220043420792
|
| Exact Mass |
233.068
|
| CAS # |
1443448-82-5
|
| Related CAS # |
SEMBL;1443448-82-5
|
| PubChem CID |
137647276
|
| Appearance |
White to off-white solid powder
|
| LogP |
1.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
352
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C(C(=C)[C@@H](C1)NC(C1C=CC=CC=1O)=O)=O
|
| InChi Key |
SBEBFCLNXGMFOQ-SECBINFHSA-N
|
| InChi Code |
InChI=1S/C12H11NO4/c1-7-9(6-17-12(7)16)13-11(15)8-4-2-3-5-10(8)14/h2-5,9,14H,1,6H2,(H,13,15)/t9-/m1/s1
|
| Chemical Name |
2-hydroxy-N-[(3S)-4-methylidene-5-oxooxolan-3-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~428.78 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2878 mL | 21.4390 mL | 42.8780 mL | |
| 5 mM | 0.8576 mL | 4.2878 mL | 8.5756 mL | |
| 10 mM | 0.4288 mL | 2.1439 mL | 4.2878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
